NASDAQ: BBIO

BridgeBio Pharma (BBIO) Stock Analysis & Forecast

Nov 13 close

$78.30+0.13 (+0.2%)

Gekko Brief

AI summaryNov 9 close

BridgeBio reported stronger third-quarter 2026 results, with revenue of $353.17 million and a net loss of $56.71 million, an improvement from the prior year. The quarter's narrative centers on Attruby, which the company said is annualizing to over $1 billion in U.S. revenue, alongside anticipation of upcoming launches including BBP-418, with an FDA decision nearing on November 27, infigratinib, and encaleret. The company also announced equity grants to new employees and plans to present new acoramidis data at the American Heart Association Scientific Sessions 2026, while management is set to appear at several investor conferences in November and December.

BBIO closed at $77.93, up 4.9%, sitting above both its 50-day average of $69.79 and 200-day average of $72.68. The GekkoIndex reads 47, placing the stock in the Neutral zone. Shares trade 7.9% below Gekko Fair Value of $84.60. One-month return stands at 19.3%, though the three-month return is negative at -6.9%, reflecting mixed short-term performance against a stronger six-month return of 20.5%.

The next earnings date falls on 23 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows, though one billionaire holder is recorded. Seasonality data shows the next 20 trading days have averaged a 2.8% return over 5 years, with gains in 4 of those years. The pending BBP-418 FDA decision on 27 November and continued Attruby commercial progress remain relevant through this period, alongside consensus analyst coverage showing 17 buy ratings among 18 firms.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

BridgeBio Pharma price vs fair value

$84.73$78.30Nov ’25May ’26Nov ’26
Close $78.30200-day averageGekko Fair Value $84.73

BridgeBio Pharma quick facts

Market cap
$15.25B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$3.03
Revenue, TTM
$945.5M
Profit margin
-59.8%
Dividend yield
—
Beta
0.94
Volume
1.15M avg 3.01M
1-year return
+18.2%
Typical daily move
±3.9%
Typical 20-day move
±10.4%
50-day average
$69.98
200-day average
$72.69
Next earnings
Feb 23 after close
Shares outstanding
194.8M
52-week range
$62.50$93.42

BridgeBio Pharma swing-trade checklist

BridgeBio Pharma scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $78.30 sits between the 50-day ($69.98) and 200-day ($72.69) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    50.2, Neutral

    Reading 50.2 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    7.6% below

    Price is 7.6% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +1.9% on average

    From this point in the calendar, the next 20 trading days averaged +1.9% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

BridgeBio Pharma stock chart and price history

BridgeBio Pharma closed at $78.30 on Nov 13, 2026, +18.2% over the past year, inside a 52-week range of $62.50 to $93.42.

Close50-day average200-day averageVolume
BridgeBio Pharma share price, past year, with 50-day and 200-day moving averages and volume$50$60$70$90DecJan 2026FebMarAprMayJunJulAugSepOctNov78.30

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+16.6%
3 months
−2.0%
6 months
+18.4%
1 year
+18.2%
The full BBIO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BBIO in Gekko

Follow BridgeBio Pharma through every session

Put BBIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BBIO in GekkoFree for 7 days. No credit card required.

About BridgeBio Pharma

BridgeBio Pharma works on finding and developing treatments for genetic conditions, following candidates from early research through late-stage clinical testing. Its pipeline includes a small molecule meant to stabilize transthyretin for a heart condition tied to transthyretin amyloidosis, a molecule targeting a childhood bone-growth disorder, a gene transfer candidate for a hormonal condition affecting the adrenal glands, a compound aimed at a rare form of low blood calcium, and a program addressing recurring kidney stones and related hyperoxaluria. Some of these programs have reached mid to late-stage clinical trials, while others remain in earlier testing.

The company also pursues work in rare Mendelian disorders, cancer-related diseases, and gene therapy more broadly, running roughly thirty development programs at once. It carries out some of this work through licensing and collaboration arrangements with outside research institutions, including a major university, a state university system, and a biomedical research organization, which support parts of its scientific pipeline.

BridgeBio Pharma was established in 2015 and is headquartered in Palo Alto, California. Its shares are listed on the NASDAQ under the ticker BBIO.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
bridgebio.com

BridgeBio Pharma GekkoIndex: the smart money zone

BridgeBio Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.2, in the Neutral zone, up 1.9 points over five sessions.

010050.2Neutral

Up 1.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying35+1.4%+2.3%+2.1%+5.5%
Accumulation194+1.3%+2.3%+3.3%+8.3%
Neutral (current zone)434+0.5%+1.2%+2.6%+7.8%
Distribution37−0.2%−1.3%+0.4%+1.6%
Selling2Too few readings yet

Average BBIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the BBIO price, zone by zone.Track BBIO in Gekko

Is BridgeBio Pharma stock overvalued? Gekko Fair Value

BridgeBio Pharma trades 7.6% below Gekko Fair Value of $84.73, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what BridgeBio Pharma shares are worth, recalculated every trading day.

$84.73

Gekko Fair Value, Nov 14, 2026

7.6% Undervalued

At the end of Aug 2026 the price was 22.2% below the estimate.

Gekko Fair ValueShare price, month end
$85$78Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BBIO in Gekko

BridgeBio Pharma insider and Congress trading

No open-market insider purchases were filed for BridgeBio Pharma, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BBIO in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BBIO insider filing, plotted on the chart in Gekko.Open BBIO in Gekko

Congress trades last 90 days

No trades in BBIO were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BBIO, plotted on the chart in Gekko.Open BBIO in Gekko

Buybacks

BridgeBio Pharma has been buying back its own shares.

Latest authorization
$500.0M, May 7, 2026
Bought back, quarter ended Sep 30, 2026
$42.50M
As a share of market cap
0.28%

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds BBIO.

0added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

BridgeBio Pharma earnings: next date and track record

BridgeBio Pharma reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 1 of its last 8 reports.

1 of 8reports beat the EPS estimate
±3.3%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

+1.5%Feb ’25+6.9%Apr ’25−6.2%Aug ’25−1.8%Oct ’25−2.0%Feb ’26−1.0%May ’26−0.9%Aug ’26+5.8%Oct ’26

Last earnings call, Oct 29, 2026 AI summary

What they said
BridgeBio reported Attruby (acoramidis) annualizing to over $1 billion in U.S. revenue, with strong European performance as the leading brand. The company holds second place in new patient starts in the TTR market, dominant in first-line settings. Three additional launches are expected within 7 months, including BBP-418 (imminent), infigratinib (PDUFA February 4), and encaleret (PDUFA May 8), all with priority review.
Guidance
Management reaffirmed $4 billion peak year sales target for Attruby and projects an additional $4 billion combined peak sales across three pipeline products. The company expects continued revenue growth and improving competitive positioning as reimbursement dynamics evolve.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 29, 2026−$0.42
est −$0.54
+22.5%$353.2M
est $293.5M
+20.3%+5.8%
Aug 10, 2026−$0.78
est −$0.58
−35.5%$243.7M
est $220.9M
+10.3%−0.9%
May 7, 2026−$0.84
est −$0.62
−35.5%$194.5M
est $178.1M
+9.2%−1.0%
Feb 24, 2026−$0.94
est −$0.72
−31.1%$154.2M
est $146.8M
+5.0%−2.0%
Oct 29, 2025−$0.95
est −$0.88
−8.0%$120.7M
est $148.2M
−18.5%−1.8%
Aug 5, 2025−$0.95
est −$0.83
−14.5%$110.6M
est $108.1M
+2.3%−6.2%
Apr 29, 2025−$0.99
est −$0.89
−11.1%$116.6M
est $68.41M
+70.5%+6.9%
Feb 20, 2025−$1.37
est −$1.09
−26.1%$5.88M
est $4.04M
+45.6%+1.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

BridgeBio Pharma stock forecast and analyst price targets

Analysts’ average 12-month price target for BridgeBio Pharma is $106.85, +36.5% from the last close, from 17 firms rating the stock in the last 90 days.

$106.85consensus 12-month target, +36.5% from the last close
Low $91High $156
Buy16
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 17 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyBuy, maintained$91+16.2%
Nov 2BarclaysBuy, maintained$156+99.2%
Nov 2Canaccord GenuityBuy, maintained$108+37.9%
Oct 30CitiHold, maintained$91+16.2%
Oct 30UBSBuy, maintained$92+17.5%
+2.6%average 20-day move after past Neutral readings
+1.9%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

BridgeBio Pharma seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, BridgeBio Pharma averaged +1.9% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−20.8%2021−13.0%2022+19.4%2023+14.0%2024+12.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−8.4%1 of 5
Next 10 trading days−3.8%2 of 5
Next 15 trading days−0.1%3 of 5
Next 20 trading days+1.9%3 of 5
Next 30 trading days−7.9%3 of 5

For scale, BBIO’s typical 20-trading-day move in either direction is about 10.4%.

BridgeBio Pharma market cap and key statistics

BridgeBio Pharma’s market cap is $15.25B and revenue of $945.5M over the last twelve months.

Valuation

Market cap
$15.25B
EPS, TTM
−$3.03
Gekko Fair Value
$84.73

Trading

Volume
1.15M
Avg volume, 20 days
3.01M
52-week high
$93.42
52-week low
$62.50
Shares outstanding
194.8M

Financials

Revenue, TTM
$945.5M
Profit margin
-59.8%
Return on equity
-1790%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.94
Typical daily move
±3.9%
Typical 20-day move
±10.4%

BridgeBio Pharma peers

BridgeBio Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

BridgeBio Pharma stock FAQ

What is BridgeBio Pharma’s market cap?

BridgeBio Pharma’s market cap is $15.25B at the Nov 13, 2026 close of $78.30, with 194.8M shares outstanding.

What is the BridgeBio Pharma stock forecast?

The consensus analyst 12-month price target for BridgeBio Pharma is $106.85, +36.5% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is BridgeBio Pharma stock overvalued or undervalued?

On Gekko’s estimate BridgeBio Pharma is undervalued: the Nov 13, 2026 close of $78.30 is 7.6% below Gekko Fair Value of $84.73. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does BridgeBio Pharma report earnings next?

BridgeBio Pharma is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of −$0.59 per share on revenue of $310.8M. BridgeBio Pharma beat the earnings estimate in 1 of its last 8 reports, moving 3.3% on average across the report.

What is BridgeBio Pharma’s 52-week high and low?

BridgeBio Pharma’s 52-week high is $93.42 and its 52-week low is $62.50; it closed at $78.30 on Nov 13, 2026, +18.2% over the past year.

Is BridgeBio Pharma stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See BridgeBio Pharma the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.